Amarin Corporation plc (ADR) (AMRN) Releases Earnings Results, Beats Expectations By $0.06 EPS

Amarin Corporation plc (ADR) (AMRN) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.07 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.06. Analysts had a consensus of $-0.13. The company posted revenue of $32.81 million in the period, compared to analysts expectations of $29.30 million. The company’s revenue was up 85.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.15 EPS.

Many Wall Street Analysts have commented on Amarin Corporation plc (ADR). Amarin Corporation plc (ADR) was Resumed by Jefferies to “Buy” on May 12, 2016.

Amarin Corporation plc (ADR) opened for trading at $2.94 and hit $3.19 on the upside on Tusday, eventually ending the session at $3.18, with a gain of 9.28% or 0.27 points. The heightened volatility saw the trading volume jump to 1,66,61,310 shares. Company has a market cap of $589 M.

In a different news, on Feb 3, 2016, John F Thero (CEO) purchased 25,000 shares at $1.37 per share price.

Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarin’s lead product Vascepa (icosapent ethyl) capsules are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia. The Company sells Vascepa principally to various wholesalers as well as regional wholesalers and specialty pharmacy providers who in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Vascepa is available in the United States by prescription only. Amarin is also developing Vascepa for the treatment of patients with high (TG over 200 milligrams per deciliter and less than 500 milligrams per deciliter) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels.

Amarin Corporation plc (ADR)

Leave a Reply

Amarin Corporation plc (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amarin Corporation plc (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.